OLIG3 Inhibitors
OLIG3 inhibitors represent a class of chemical agents designed to modulate the activity of the OLIG3 protein, a member of the oligodendrocyte lineage transcription factors that are crucial in the development of the central nervous system. OLIG3, part of the basic helix-loop-helix (bHLH) family of transcription factors, plays a pivotal role in the regulation of neuronal differentiation and the development of specific neural circuits. It is primarily involved in patterning within the ventral neural tube, and its expression helps define neuronal identities during early embryogenesis. OLIG3 is expressed in various regions of the developing brain and spinal cord, contributing to the specification of neuronal subtypes in the dorsal spinal cord, where it helps regulate the balance between excitatory and inhibitory neurons. Inhibition of OLIG3 can result in alterations in these developmental pathways, making OLIG3 inhibitors an interesting subject of study for understanding neural differentiation and lineage specification.
At the molecular level, OLIG3 inhibitors target the binding activity of OLIG3 to DNA or interfere with its interactions with other cofactors necessary for its transcriptional regulatory functions. By inhibiting this protein, researchers can investigate the downstream effects on gene expression patterns that influence the development of specific neuronal subpopulations. OLIG3's interactions with other transcription factors like Pax6, Nkx6.1, and Sox genes are critical for the precise regulation of neural progenitor cells, making its inhibition a valuable tool in mapping neural development pathways. Additionally, studying OLIG3 inhibitors provides insight into how transcriptional repression or activation via OLIG3 modulates the broader bHLH network, which governs the differentiation of glial and neuronal cells. These inhibitors also serve as key reagents in dissecting the molecular mechanisms underlying neural circuit formation, which are essential for understanding the complexity of brain and spinal cord development.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits cyclin-dependent kinases (CDKs), which are key regulators of cell cycle progression and gene expression. Inhibition of CDKs can lead to reduced phosphorylation of downstream targets, including transcription factors that may regulate OLIG3 activity. Thus, Alsterpaullone can inhibit OLIG3 by preventing the activation of transcription factors that promote its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3Ks), which participate in signaling pathways that can lead to the activation of downstream targets such as AKT. Inhibition of PI3K/AKT signaling can reduce the phosphorylation and activity of transcription factors that are involved in OLIG3 function, thereby inhibiting OLIG3's role in neuronal development and differentiation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is part of the MAPK/ERK pathway. This pathway can influence the expression and function of various transcription factors that regulate the activity of proteins such as OLIG3. By inhibiting MEK, PD98059 prevents the activation of ERK and subsequent transcriptional events that would normally enhance OLIG3 activity, thereby functionally inhibiting OLIG3. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. The p38 MAPK pathway is implicated in inflammatory responses and can modulate the activity of various transcription factors. Inhibition of p38 MAPK can lead to decreased activity of transcription factors that would otherwise contribute to OLIG3 function, thereby functionally inhibiting OLIG3. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which is involved in the regulation of transcription factors that can control the expression of genes downstream of OLIG3. By inhibiting JNK, SP600125 can prevent the activation of these transcription factors, leading to a functional inhibition of OLIG3 by limiting its regulatory influence on neuronal differentiation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream activators of the ERK pathway. The ERK pathway can regulate transcription factors that control OLIG3 function. By inhibiting MEK1/2, U0126 prevents the phosphorylation and activation of ERK, leading to functional inhibition of OLIG3 by impairing the transcriptional regulation of genes involved in its activity. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
Chir99021 inhibits glycogen synthase kinase 3 (GSK-3), which is involved in the regulation of numerous cellular processes, including those influencing transcription factors that regulate OLIG3 activity. Inhibition of GSK-3 can lead to stabilization and activation of these transcription factors, thereby functionally inhibiting OLIG3 by altering its transcriptional control. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). ROCK can influence cytoskeletal organization and is implicated in the regulation of transcription factors that can affect OLIG3 activity. Inhibition of ROCK by Y-27632 can lead to altered transcription factor activity, functionally inhibiting OLIG3 by changing its influence on gene expression related to neuronal development. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Dorsomorphin inhibits BMP signaling by targeting the BMP type I receptors ALK2, ALK3, and ALK6. BMP signaling can regulate transcriptional events that influence OLIG3 function. By inhibiting this pathway, Dorsomorphin can functionally inhibit OLIG3 by preventing the BMP-mediated transcriptional activation of genes that OLIG3 regulates. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
XAV939 inhibits Tankyrase, leading to stabilization of Axin and inhibition of the Wnt/β-catenin signaling pathway. This pathway can influence the activity of transcription factors that regulate OLIG3 function. By inhibiting Tankyrase with XAV939, the Wnt/β-catenin pathway is downregulated, which can functionally inhibit OLIG3 by altering its transcriptional control mechanisms. | ||||||